GlassScriptPhysician profile
Albert Yt Wu
NPI 1053721696
$4,865.45
in general payments reported to CMS, 2019-2025
27 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2020: $1,024 · 2021: $1,703 · 2022: $908 · 2023: $150 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $326.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,088.27 | 2019-2022 | |
| Glaxosmithkline, LLC. | $962.10 | 2019-2022 | |
| Genzyme Corporation | $659.60 | 2020-2025 | |
| Optinose US, INC. | $336.36 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $291.64 | 2019-2025 | Dupixent |
| Kaleo, INC. | $223.46 | 2019-2021 | |
| Pfizer INC. | $194.37 | 2019-2022 | |
| Abbvie INC. | $147.98 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $125.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $116.74 | 2019 | |
| Mylan Specialty L.P. | $85.71 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.86 | 2020-2021 | |
| Amgen INC. | $61.66 | 2021-2022 | |
| Grifols USA, LLC | $58.82 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $51.60 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $48.32 | 2020-2021 | |
| Alk-Abello, INC | $42.84 | 2020-2021 | |
| Genentech USA, INC. | $40.63 | 2020-2021 | |
| Leo Pharma INC. | $40.34 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.68 | 2021 | |
| Sanofi Pasteur INC. | $36.08 | 2020-2021 | |
| Adma Biomanufacturing LLC | $30.76 | 2021 | |
| Csl Behring | $30.06 | 2021 | |
| Pharming Healthcare, INC. | $26.96 | 2022 | |
| Incyte Corporation | $21.87 | 2021 | |
| Shire North American Group INC | $18.61 | 2019 | |
| Phadia US INC. | $17.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.